HAVCR2 and neoplasm: A phase I/Ib clinical trial also showed that sabatolimab, an anti-TIM-3 antibody in combination of anti-PD-1 antibody, exhibited preliminary signs of anti-tumor activity, which provide a new therapeutic plan for PD-1 treatment-unresponsive cohort [6].